한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제24권1호
  • /
  • Pages.1-8
  • /
  • 2014
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

고관절치환술 후의 Rivaroxaban의 국내임상적용

Rivaroxaban in Patients Undergoing Hip Arthroplasty in Korean Patients: Implications in Clinical Practice

  • 유옥리 (이화여자대학교 임상보건과학대학원) ;
  • 나현오 (가톨릭대학교 서울성모병원 약제부) ;
  • 이정연 (이화여자대학교 임상보건과학대학원)
  • Liu, Yu Li (Graduate School of Clinical Health Sciences, Ewha Womans University) ;
  • La, Hyen O (Seoul St. Mary's Hospital) ;
  • Rhie, Sandy Jeong (Graduate School of Clinical Health Sciences, Ewha Womans University)
  • 투고 : 2014.01.12
  • 심사 : 2014.03.19
  • 발행 : 2014.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Currently, rivaroxaban is widely used clinically for thromboprophylaxis after surgery. However, there are concerns on effectiveness and safety of rivaroxaban for its proper use. We aimed to evaluate the effectiveness and safety of rivaroxaban in orthopaedic patients after total hip replacement surgery in a large medical centre after the preferred formulary was switched from enoxaparin to rivaroxaban. Methods: The study was conducted on the patients who underwent hip arthroplasty surgery at the department of Orthopaedic Surgery at Seoul St. Mary's Hospital, South Korea. Electronic medical records were retrospectively reviewed to identify patients treated with rivaroxaban following total hip replacement between February 2011 and March 2012. Evaluation criteria included indications for use, dose, initiation and duration of therapy, drug interactions, adverse reactions, and status of health care reimbursement. The patients who were on enoxaparin were also reviewed as a reference. Results: We identified 57 patients who received rivaroxaban and 50 who received enoxaparin. All patients were prescribed the drugs for Korean Food and Drug Administration-approved indications. No thromboembolic or bleeding events were observed in either group. However, only 5.3% of rivaroxaban- treated patients had an appropriate length of prophylaxis and only 3.5% began rivaroxaban treatment at the recommended time. Surprisingly, 47.4% of rivaroxaban-treated patients received rivaroxaban despite being ineligible for reimbursement benefits. Conclusion: Rivaroxaban was generally well tolerated clinically. However, the duration of treatment, the time of initiation and patient eligibility for reimbursement require improvements, emphasising the need for education which indicates the area of pharmacists' involvement.

키워드

참고문헌

  1. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163(7): 759-68. https://doi.org/10.1001/archinte.163.7.759
  2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Chest Physicians Evidence-Based Clinical Thrombosis (9th ed.). American College of Practice Guidelines. Chest 2012; 141: e419S-e494S.
  3. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis (9th ed.). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e278S-325S. https://doi.org/10.1378/chest.11-1986
  4. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48(1): 1-22. https://doi.org/10.2165/0003088-200948010-00001
  5. Eriksson BI, Quinlan DJ. Oral anticoagulants in development; focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66(11): 1411-29. https://doi.org/10.2165/00003495-200666110-00001
  6. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3(3): 514-21. https://doi.org/10.1111/j.1538-7836.2005.01166.x
  7. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59- 7939-a novel, oral direct factor Xa inhibitor-on clotbound factor Xa activity in vitro [Abstract]. J Thromb Haemost 2005; 3 Suppl 1: P1104. https://doi.org/10.1111/j.1538-7836.2005.01318.x
  8. Bayer Schering Pharma.$ Xarelto^{(R)}$ (rivaroxaban 10 mg tablets): EU summary of product characteristics. Available on the internet:http://www.xarelto.com/en/ information-onxarelto/ vte-prevention-in-orthopaedic-surgery. [Last accessed June 2, 2013].
  9. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa ingibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37(5): 1056-64. https://doi.org/10.1124/dmd.108.025569
  10. Kakkar AK, Brenner B, Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372(9632): 31-9. https://doi.org/10.1016/S0140-6736(08)60880-6
  11. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358(26): 2765-75. https://doi.org/10.1056/NEJMoa0800374
  12. Grégoire JP, Moisan J, Potvin L, et al. Effect of drug utilization reviews on the quality of in-hospital prescribing: a quasi-experimental study. BMC Health Services Research 2006; 6: 33. https://doi.org/10.1186/1472-6963-6-33
  13. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis (9th ed.). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012; 141: e24S-e43S.
  14. National Institute for Health and Care Excellence (NICE) Guideline. Final appraisal determination-Rivaroxaban for prevention of venous thromboembolism after total hip or knee replacement in adults.Issue date: February 2009 Available on the internet: http://www.nice.org.uk/nicemedia/pdf/ RivaroxabanFAD.pdf. [Last accessed July 12, 2013].
  15. Phillips MS, Gayman JE, Todd MW, et al. ASHP guidelines on medication-use evaluation. Am J Health Syst Pharm 1996; 53: 1953-5.
  16. Health Insurance Reviews & Assessment Service. Healthcare Benefits Management. Available on the internet: http:// www.hira.or.kr. [Last accessed June 14, 2013].
  17. Bergqvist D, Benoni G, Björgell O, et al. Low-molecularweight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335(10): 696-700. https://doi.org/10.1056/NEJM199609053351002
  18. Planes A, Vochelle N, Darmon JY, et al. Risk of deepvenous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348(9022): 224-8. https://doi.org/10.1016/S0140-6736(96)01453-5
  19. Eikelboom JW, Quinlan DJ, Douketis JD. Extendedduration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358(9275): 9-15. https://doi.org/10.1016/S0140-6736(00)05249-1
  20. Hull RD, Pineo GF, Stein PD, et al. Extended out-ofhospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135(10): 858-69. https://doi.org/10.7326/0003-4819-135-10-200111200-00006
  21. O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 2003; 163(11): 1362-6. https://doi.org/10.1001/archinte.163.11.1362
  22. Sanofi Korea. Product information. Clexane $Injection^{(R)}$. Updated on April 22 2011. Available on the internet: http:// products.sanofi.co.kr/KR_Clexane_inj.pdf. [Last accessed May 22, 2013].
  23. Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004; 64 Suppl 1: 17-25. https://doi.org/10.2165/00003495-200464001-00004
  24. Agnelli G, Taliani MR, Verso M. Building effective prophylaxis of deep vein thrombosis in the outpatient setting. Blood Coagul Fibrinolysis 1999; 10 Suppl 2:S29-35.
  25. Xing KH, Morrison G, Lim W, et al. Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials. Thromb Res 2008; 123(1): 24-34. https://doi.org/10.1016/j.thromres.2008.05.005
  26. Fujita S, Hirota S, Oda T, et al. Deep venous thrombosis after total of knee arthroplasty in patients in Japan. Clin Orthop Relat Res 2000; (300): 168-74.
  27. Won MH, Lee GW, Lee TJ, et al. Prevalence and risk factors of thromboembolism after joint arthroplasty without chemical thromboprophylaxis in an Asian population. J Arthroplasty 2011; 26(7): 1106-11. https://doi.org/10.1016/j.arth.2010.11.005
  28. Kim YH, Suh JS. Low incidence of deep-vein thrombosis after cementless total hip replacement. J Bone Joint Surg Am 1988; 70(6): 878-82.
  29. Yoo MC, Kang CS, Kim YH, et al. A prospective randomized study on the use nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. Int Orthop 1997; 21(6): 399-402.
  30. Zindel S, Stock S, Müller D, et al. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res 2012; 12: 192-205. https://doi.org/10.1186/1472-6963-12-192
  31. Duran A, Sengupta N, Diamantopoulos A, et al. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. Pharmacoeconomics 2012; 30(2): 87-101. https://doi.org/10.2165/11599370-000000000-00000
  32. McDonald H, Diamantopoulos A, Wells P, et al. Costeffectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. J Med Econ 2012; 15(5): 817-28. https://doi.org/10.3111/13696998.2012.684116
  33. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91. https://doi.org/10.1056/NEJMoa1009638